A Compartment Based Model for the formation of 2-LTR Circles after Raltegravir Intensification

Proceedings of the IEEE Conference on Decision and Control

Volumn 2012-January, Issue , 2012, Pages 4924-4929

  Cardozo, E Fabian ^a   Vargas, Cesar A ^a   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNAMICS; PATIENT TREATMENT; VIRUSES;

ANATOMICAL LOCATIONS; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HUMAN IMMUNODEFICIENCY VIRUS; INTEGRASE; LIMITS OF DETECTION; LYMPH NODE; MULTI-COMPARTMENT MODELS; VIRAL LOAD;

DISEASES;

EID: 84878624568     PISSN: 07431546     EISSN: 25762370     Source Type: Conference Proceeding    
DOI: 10.1109/CDC.2012.6426088     Document Type: Conference Paper

References (23)

1. S. M. Hammer, J. J. Eron, P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. G. Montaner, D. D. Richman, P. G. Yeni, P. A. Volberding, and I. A. Society-USA, “Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel,” JAMA, vol. 300, no. 5, pp. 555–570, Aug. 2008.
2. S. H. Michaels, R. Clark, and P. Kissinger, “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.” N Engl J Med, vol. 339, no. 6, pp. 405–406, Aug. 1998.
3. S. Frost, J. Martinez-Picado, L. Ruiz, B. Clotet, and A. Brown, “Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.” J Virol, vol. 76, no. 3, pp. 968–979, Feb. 2002.
4. G. Dornadula, H. Zhang, B. VanUitert, J. Stern, L. Livornese, M. J. Ingerman, J. Witek, R. J. Kedanis, J. Natkin, J. DeSimone, and R. J. Pomerantz, “Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.” JAMA, vol. 282, no. 17, pp. 1627–1632, Nov. 1999.
5. M. D. Marsden and J. A. Zack, “Eradication of HIV: current challenges and new directions.” J Antimicrob Chemother, vol. 63, no. 1, pp. 7–10, Jan. 2009.
6. M.-C. Bowman, N. M. Archin, and D. M. Margolis, “Pharmaceutical approaches to eradication of persistent HIV infection.” Expert Rev Mol Med, vol. 11, p. e6, 2009.
7. R. J. Pomerantz, “Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.” HIV clinical trials, vol. 4, no. 2, pp. 137–143, Feb. 2003.
8. L. Geeraert, G. Kraus, and R. J. Pomerantz, “Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection.” Annu Rev Med, vol. 59, pp. 487–501, 2008.
9. R. J. Pomerantz, “Eliminating HIV-1 reservoirs.” Curr Opin Investig Drugs, vol. 3, no. 8, pp. 1133–1137, Aug. 2002.
10. M. Sharkey, D. Z. Babic, T. Greenough, R. Gulick, D. R. Kuritzkes, and M. Stevenson, “Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.” PLoS Pathog., vol. 7, no. 2, p. e1001303, Feb. 2011.
11. M. J. Buzón, M. Massanella, J. M. Llibre, A. Esteve, V. Dahl, M. C. Puertas, J. M. Gatell, P. Domingo, R. Paredes, M. Sharkey, S. Palmer, M. Stevenson, B. Clotet, J. Blanco, and J. Martinez-Picado, “HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects,” Nat Med, vol. 16, no. 4, pp. 460–5, Apr 2010.
12. J. M. Llibre, M. J. Buzón, M. Massanella, A. Esteve, V. Dahl, M. C. Puertas, P. Domingo, J. M. Gatell, M. Larrouse, M. Gutierrez, S. Palmer, M. Stevenson, J. Blanco, J. Martinez-Picado, and B. Clotet, “Treatment intensification with raltegravir in subjects with sustained HIV–1 viraemia suppression: a randomized 48 weeks study.” Antivir Ther (Lond), vol. 17, no. 2, pp. 355–64, June 2011.
13. D. Finzi, J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. F. Siliciano, “Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy,” Nat Med, vol. 5, no. 5, pp. 512–517, May 1999.
14. B. Ramratnam, S. Bonhoeffer, J. Binley, A. Hurley, L. Zhang, J. E. Mittler, M. Markowitz, J. P. Moore, A. S. Perelson, and D. D. Ho, “Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.” The Lancet, vol. 354, no. 9192, pp. 1782–1785, Nov. 1999.
15. X. J. Zhou, D. V. Havlir, D. D. Richman, E. P. Acosta, M. Hirsch, A. C. Collier, P. Tebas, J. P. Sommadossi, and AIDS Clinical Trials Study 343 Investigators, “Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.” AIDS, vol. 14, no. 18, pp. 2869–2876, Dec. 2000.
16. V. Dahl, L. Josefsson, and S. Palmer, “Hiv reservoirs, latency, and reactivation: Prospects for eradication,” Antiviral Research, vol. 85, no. 1, pp. 286 – 294, 2010.
17. M. Wayengera, “Targeting persistent hiv infection: Where and how, if possible?” HIV & AIDS Review, vol. 10, no. 1, pp. 1 – 8, 2011.
18. D. Callaway and A. Perelson, “Hiv-1 infection and low steady state viral loads,” Bulletin of Mathematical Biology, vol. 64, pp. 29–64, 2002.
19. D. Wodarz and M. A. Nowak, “Specific therapy regimes could lead to long-term immunological control of HIV,” Proc Natl Acad Sci USA, vol. 96, no. 25, pp. 14 464–14 469, Dec. 1999.
20. R. Luo, M. J. Piovoso, J. Martinez-Picado, and R. Zurakowski, “HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.” PLoS ONE, vol. 7, no. 7, p. e40198, Mar. 2012.
21. R. Luo, L. Cannon, J. Hernandez, M. Piovoso, and R. Zurakowski, “Controlling the evolution of resistance,” Journal of Process Control, vol. 21, no. 3, pp. 367–378, 2010.
22. R. Luo, M. Piovoso, J. Martinez-Picado, and R. Zurakowski, “Optimal antiviral switching to minimize resistance risk in HIV therapy,” PLoS ONE, vol. 6, no. 11, p. e27047, 2011.
23. E. Cardozo and R. Zurakowski, “Robust closed-loop minimal sampling method for HIV therapy switching strategies,” IEEE T Bio-Med Eng, vol. 59, no. 8, pp. 2227–2234, 2012.